Cargando…

INADEQUATE IMMUNE RESPONSE TO COVID-19 VACCINES IN THE PRESENCE OF DISEASE-MODIFYING ANTIRHEUMATIC DRUGS (DMARDS)

Detalles Bibliográficos
Autores principales:	KRISHNAIAH, AISHWARYA, KAUR, GURSHARAN, MANDAL, SANDEEP
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American College of Chest Physicians. Published by Elsevier Inc. 2022
Materias:	Chest Infection
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9549011/ http://dx.doi.org/10.1016/j.chest.2022.08.328

Ejemplares similares

Molecular mechanisms of resistance to disease modifying antirheumatic drugs (DMARDs)
por: Jansen, G, et al.
Publicado: (2002)

Frequency and trends of disease‐modifying antirheumatic drug (DMARD) use in Germany
por: Fassmer, Alexander M., et al.
Publicado: (2016)

Diabetes-Modifying Antirheumatic Drugs: The Roles of DMARDs as Glucose-Lowering Agents
por: Infante, Marco, et al.
Publicado: (2022)

TRAJECTORY OF MODIFIED MEDICAL RESEARCH COUNCIL DYSPNEA RATINGS IN PATIENTS WITH COVID-19 DISCHARGED FOLLOWING A HOSPITALIZATION OR ED ENCOUNTER
por: MICHALOPOULOS, C., et al.
Publicado: (2022)

MYOCARDITIS LINKED TO PFIZER-BIONTECH COVID-19 VACCINE
por: PRATAP SINGH, VIJAY, et al.
Publicado: (2021)

DOES COVID-19 INCREASE YOUR RISK OF DEVELOPING HAIRY CELL LEUKEMIA?
por: MANDAL, SHOBHA, et al.
Publicado: (2022)

Different humoral but similar cellular responses of patients with autoimmune inflammatory rheumatic diseases under disease-modifying antirheumatic drugs after COVID-19 vaccination
por: Andreica, Ioana, et al.
Publicado: (2022)

Cost-utility analysis of biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) combined with methotrexate for Thai rheumatoid arthritis patients with high disease activity
por: Prawjaeng, Juthamas, et al.
Publicado: (2023)

A CASE REPORT ON EXTENSIVE ARTERIAL THROMBOSIS AS A COMPLICATION OF COVID-19 INFECTION
por: MANDAL, SHOBHA, et al.
Publicado: (2021)

UNDERSTANDING COVID-19 VACCINE HESITANCY: REASONS FOR VACCINE REFUSAL FROM PATIENTS EVALUATED IN A FLORIDA ICU
por: GUREVICH, S.
Publicado: (2022)

DNA Methylation Signatures of Response to Conventional Synthetic and Biologic Disease-Modifying Antirheumatic Drugs (DMARDs) in Rheumatoid Arthritis
por: Wang, Susan Siyu, et al.
Publicado: (2023)

Tapering glucocorticoids and risk of flare in rheumatoid arthritis on biological disease-modifying antirheumatic drugs (bDMARDs)
por: Adami, Giovanni, et al.
Publicado: (2023)

VACCINE-INDUCED ANTIBODY DEPENDENT ENHANCEMENT IN COVID-19
por: SRIDHAR, PRIYANKA, et al.
Publicado: (2022)

SIGNIFICANT REDUCTION IN MORTALITY RATE IN CRITICALLY ILL PATIENTS WITH COVID-19 WITH THE IMPLEMENTATION OF A TREATMENT PROTOCOL-EXPERIENCE OF A TERTIARY CARE CENTER IN MIDWESTERN UNITED STATES DURING THE FIRST PEAK OF THE COVID-19 PANDEMIC
por: GUPTA, SANDEEP, et al.
Publicado: (2021)

PATIENT ON RITUXIMAB CONTRACTING COVID-19 VIRUS AFTER VACCINATION
por: KHAN, AWAB, et al.
Publicado: (2021)

VACCINATED WITH A TWIST: BREAKTHROUGH COVID-19 IN AN IMMUNOCOMPROMISED PATIENT
por: DAOUD, DANA, et al.
Publicado: (2021)

COMPLICATIONS OF HIGH-DOSE STEROIDS IN COVID-19
por: KAUR, TANISHA, et al.
Publicado: (2021)

SEVERE COVID-19 PNEUMONIA IN A FULLY VACCINATED IMMUNOCOMPROMISED PATIENT
por: SUBRAMANIAN, LAKSHMI, et al.
Publicado: (2021)

A CASE OF COVID-19 PRESENTING WITH ENCEPHALOPATHY, POST-INFECTIOUS NEUROPSYCHIATRIC SEQUELAE, AND ACCELERATED WORSENING OF CHRONIC COMORBIDITIES
por: DAGOGO-JACK, IBIMINA, et al.
Publicado: (2021)

SEVERE/REFRACTORY IMMUNE THROMBOCYTOPENIA IN MILD COVID-19 DISEASE
por: MENON, TRISHALA, et al.
Publicado: (2021)

A CASE OF COVID-19 PNEUMONIA IN A VACCINATED PATIENT WITH PSORIATIC ARTHRITIS
por: CHAO, C., et al.
Publicado: (2022)

SEVERE ALLERGIC ERYTHEMATOUS REACTION POSTMESSENGER RNA-BASED COVID-19 VACCINE
por: ALI, RUHMA, et al.
Publicado: (2022)

ORAL MANIFESTATIONS OF COVID-19 INFECTION: AN ANALYTICAL CROSS SECTIONAL STUDY
por: CHAUDHRY, K., et al.
Publicado: (2022)

THE SUBSEQUENT IMPACT OF COVID-19 FOR BOTH IMMUNE DYSREGULATION AND OPPORTUNISTIC INFECTIONS
por: SUH, CLARA, et al.
Publicado: (2022)

HEMOLYTIC ANEMIA EXACERBATION IN CHRONIC PAROXYSMAL NOCTURNAL HEMOGLOBINURIA AFTER COVID-19 VACCINATION
por: YOU, JOSEPH, et al.
Publicado: (2022)

A RARE CASE OF INTERNAL JUGULAR VEIN THROMBOSIS AFTER MRNA COVID-19 VACCINE
por: HONG, SUNG, et al.
Publicado: (2021)

THE RELATIONSHIP BETWEEN SERUM ACE LEVEL AND HYPERTENSION DRUGS IN PATIENTS WITH SARS-COV-2
por: MÜCAHIT ÜNAL, ALI, et al.
Publicado: (2021)

IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME AFTER USE OF ANTI-RETROVIRAL THERAPY IN COVID-19
por: NANGRANI, KUNAL, et al.
Publicado: (2021)

THE IMPACT OF COVID-19 VACCINATION ON DISEASE SEVERITY AND OUTCOMES IN HOSPITALIZED PATIENTS: A REAL-WORLD EXPERIENCE
por: SATISH, V., et al.
Publicado: (2022)

A CASE OF SARS-COV-2 ASSOCIATED WITH QUADRUPLE BACTERIAL COINFECTION
por: JIMENEZ, KATIRIA PINTOR, et al.
Publicado: (2022)

SURVEY OF KNOWLEDGE, ATTITUDES, AND BEHAVIORS OF PRIMARY CARE PROVIDERS AND PULMONOLOGISTS CONCERNING INFLUENZA, PNEUMOCOCCAL, AND COVID-19 VACCINATION OF ADULTS
por: FELZER, JAMIE, et al.
Publicado: (2022)

MEASUREMENT OF PATIENT-REPORTED OUTCOMES AT APPROXIMATELY ONE MONTH FOLLOWING A HOSPITAL OR ED DISCHARGE FOR COVID-19
por: CARPE, S., et al.
Publicado: (2022)

Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs
por: Charles-Schoeman, Christina, et al.
Publicado: (2016)

Did the Introduction of Biosimilars Influence Their Prices and Utilization? The Case of Biologic Disease Modifying Antirheumatic Drugs (bDMARD) in Bulgaria
por: Tachkov, Konstantin, et al.
Publicado: (2021)

CRITICAL PATIENTS IN SPONTANEOUS BREATHING WITH COVID-19 IN BRAZIL: RESPONSE FROM PULMONARY AERATION TO PRONE POSITION
por: DOS SANTOS, W.S., et al.
Publicado: (2022)

Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors
por: Nash, Peter, et al.
Publicado: (2018)

Ixekizumab efficacy and safety with and without concomitant conventional disease-modifying antirheumatic drugs (cDMARDs) in biologic DMARD (bDMARD)-naïve patients with active psoriatic arthritis (PsA): results from SPIRIT-P1
por: Coates, Laura C, et al.
Publicado: (2017)

Correction: Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor inhibitors
Publicado: (2019)

Cough Frequency During Treatment Associated With Baseline Cavitary Volume and Proximity to the Airway in Pulmonary TB
por: Proaño, Alvaro, et al.
Publicado: (2018)

AN ISOLATED PLEURAL EFFUSION AS A SEQUELA OF COVID-19 INFECTION
por: Patel, Rutwik, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_h85vahmtpmh2kv1klm7qjb0764